Etiracetam
Racemic precursor of levetiracetam: the ethyl analog of piracetam whose active S-enantiomer binds SV2A.
Pharmacology
Contents
WHAT IS ETIRACETAM?
Detailed overview
Etiracetam is the racemic (RS) mixture of which levetiracetam is the active (S)-enantiomer; the (R)-enantiomer (ucb L060) is largely inactive. Developed by UCB in the late 1970s as an ethyl analog of piracetam, it was first explored as a nootropic, but its cognitive effects in humans proved weak, while the (S)-enantiomer showed a distinctive anticonvulsant profile and became the widely prescribed epilepsy drug levetiracetam (Keppra). Its active enantiomer works by binding synaptic vesicle protein SV2A, modulating presynaptic neurotransmitter release and reducing neuronal hyperexcitability. Etiracetam itself is now essentially of historical and reference interest: the racemate is not marketed, and human data on it come from only a handful of small studies around 1980 (PMID 6771807, 7312895, 7006304).
Mechanism
SV2A ligand (via active S-enantiomer)
Half-life
~6-8 h (active enantiomer)
Composition
Racemate: 50% levetiracetam + 50% inactive (R)
Legal status
Not marketed; enantiomer levetiracetam is Rx
Receptor profile
- SV2A synaptic vesicle protein (S-enantiomer)Strong
- Presynaptic neurotransmitter releaseModerate
- Reduction of neuronal hyperexcitabilityModerate
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Somnolence and sedation, the most characteristic effect of the active enantiomer (levetiracetam)
- Irritability, mood swings or aggression (a behavioral effect documented for levetiracetam)
- Dizziness and coordination difficulty, typically dose-dependent
- Fatigue and lethargy
- Headache
- Note: safety data on the racemate itself are limited; the above are largely extrapolated from levetiracetam
Contraindications · 6
- Pregnancy and breastfeeding: limited data, should be avoided
- Psychiatric history or suicidal ideation: antiepileptic class warning, close monitoring
- Renal impairment: the active enantiomer (levetiracetam) is cleared mainly by the kidneys, dose caution
- Not a substitute for prescribed levetiracetam: the racemate is not a marketed medicine
- Alcohol and CNS depressants: additive sedation and psychomotor impairment
- Given the antiseizure pharmacology, should only be considered under medical supervision
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
Memory retrieval deficits: alleviation by etiracetam, a nootropic drug.
Sara SJ.
Behavioural effects of etiracetam in rats.
Wolthuis OL.
Influence of piracetam and etiracetam compared to placebo, on rCBF and parameters of brain metabolism.
Van Aken J, Rolly G.
Separation of Etiracetam Enantiomers Using Enantiospecific Cocrystallization with 2-Chloromandelic Acid.
Nulek T, Klaysri R, Cedeno R, et al.
Piracetam and other structurally related nootropics.
Gouliaev AH, Senning A.
FAQ
FAQ
Racemic precursor of levetiracetam: the ethyl analog of piracetam whose active S-enantiomer binds SV2A.
Telegram
Have a question about Etiracetam?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.